Finance
Siemens Healthineers Q4 sales miss, earnings outlook disappoints
Published by Global Banking and Finance Review
Posted on November 5, 2025
Editorial & Advertiser disclosure
Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
By Marleen Kaesebier and Alexander Hübner
(Reuters) -Siemens Healthineers on Wednesday reported fourth-quarter sales that were below analysts' consensus, hit by higher U.S. import tariffs, and issued an earnings outlook that disappointed investors.
The company's shares fell 12% in opening trade before paring some losses. They were down 9% at 0809 GMT, set for their biggest intraday loss ever.
The German medical technology company said that it expects comparable revenue growth to be between 5% to 6% in 2026 compared with 2025 and adjusted basic earnings per share (EPS) to be between 2.20 euros and 2.40 euros.
One local trader described the earnings outlook as "very weak" and said it would likely hurt the company's shares.
For this year, the group's comparable revenue growth of 5.9% came in at the top end of its annual guidance of 5.5% to 6%, but missed analysts' expectations of 6.3%.
Its fourth quarter revenues at 6.32 billion euros ($7.37 billion) meanwhile compared to 6.45 billion euros expected by analysts polled by Vara Research.
TARIFF IMPACTS AND MITIGATION
"Higher tariffs had a negative effect in all segments," the company said in a statement, saying these were offset by revenue development and cost reductions in the diagnostics business.
The group said it expects to face tariff-related costs of around 200 million euros this year and around 400 million euros in 2026.
In July Siemens Healthineers said it expected U.S. tariffs to have an impact between 400-500 million euros in 2026.
The company's chief finance officer Jochen Schmitz said in a call with analysts that the company was raising prices to combat the tariff impact.
"We expect tariffs to be fully mitigated over the medium term," Schmitz said, "The three main mitigation levers are market adaptive pricing, tight cost control, and if this is not sufficient, shifting value add".
($1 = 0.8575 euros)
(Reporting by Alexander Huebner in Munich and Marleen Kaesebier in Gdansk; editing by Milla Nissi-Prussak and Matt Scuffham)